On the basis of geography, the
global Human
Chorionic Gonadotropin Market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America is the
highest regional contributor to the market and is expected to continue as a
regional dominator over the forecast years. This primarily owes to the rising
number of infertility cases as well as hormonal dysfunction among young males
and females as a result of changing lifestyle. According to Mayo Clinic, around
25% of women fertility problems in the U.S. are a result of ovulation issues
that are mostly caused due to dysfunction of human chorionic gonadotropin (HCG)
hormone. Thus, the rapidly increasing cases of infertility are expected to
surge the North America global human chorionic gonadotropin market. On the other
hand, Asia Pacific is anticipated to be the fasting growing geography, owing to
economic developments facilitating technological advancements in healthcare
sectors as well as emerging local players in the market.
Human chorionic gonadotropin
hormone (HCG) is a hormone secreted by the placenta after implantation of a
fertilized zygote in the uterus. The hormone also supports normal development
of an egg and helps in the stimulation of egg release from the ovary. The HCG
is mainly used to induce ovulation in the women under infertility treatment. It
is also used among males mostly to increase the sperm count and in young boys,
due to pituitary gland disorders and other diseases, due to which the testicles
of the young males does not drop down naturally into the scrotum. The HCG is
usually administered as an injection under the skin into a muscle. The HCG can
also be administered at home under the advice of a gynecologist or a
pharmacist.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1011
The HCG levels can be determined
with the help of urine or blood test. Result of specific test helps in the
determining accurate measurement of the levels. These tests are mostly used to
identify and confirm pregnancy or as a screening test to determine birth
defects.
Rising incidence of infertility
are expected to drive the growth of human chorionic gonadotropin market across
the globe
According to Centers of Disease
Control and Prevention (CDC) in 2016, approximately 7.3 million women aged 15 -
44 have used infertility services. Moreover, 6.7% of the married women aged 15
- 44 were reported infertile. According to Azura Vascular Care, around 17% of
the couples in the U.S. deal with infertility out of which 30% cases are a
result of male infertility. These numbers suggests significant demand for
infertility treatments, such as HCG in order for females to conceive a child.
According to a statistical survey conducted by HealthGrove, pituitary gland
disorders resulted into the death of around 205 people in 2015, out of which
highest percentage belonged to white men. Pituitary disorders resulting into
significant mortality rate are propelling the demand for human chorionic
gonadotropin hormone. Additionally, various other factors such as
endometriosis, hormonal imbalance, polycystic ovary syndrome, and others are
expected to propel the growth of global HCG market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/human-chorionic-gonadotropin-market-1011
For instance, according to Frisco
Institute of Reproductive Medicine, around 10% of women of reproductive age in
the U.S. suffer from polycystic ovary syndrome. However, easy availability of
alternatives to treat infertility could act as potential barriers for the
market growth.
North America to dominate global
human chorionic gonadotropin (HCG) market, owing to rising frequency of
infertility cases
The key players operating the
global human chorionic gonadotropin market include Merck & Co., Inc., EMD
Sereno, Inc., Fresenius Kabi, Bristol Myers Squibb Company, Ferring BV, and
Kamia Biomedical Company. Acris Antibodies developed a human chorionic gonadotropin
hormone by recombinant DNA technology that helps to prevent the disintegration
of the corpus luteum of the ovary thereby, maintaining levels of progesterone
production for healthy pregnancy in females.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1011
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment